Results 61 to 70 of about 30,760,747 (299)

Ligand‐dependent transcriptional heterogeneity in cell cycle gene expression delays G1/S entry

FEBS Letters, EarlyView.
EGF and HRG induce distinct G1/S progression programs in ErbB2‐amplified BT474 breast cancer cells. Despite activating the potent ErbB2–ErbB3 heterodimer, HRG does not accelerate cell‐cycle entry. Instead, EGF promotes earlier restriction‐point passage via ERK–FOS signaling, whereas HRG activates the AKT–MYC axis, driving transcriptional heterogeneity ...
Ririn Rahmala Febri, Ayaka Nagasato‐Ichikawa, Keita Iida, Shuhei Kimura, Akira Imamoto, Mariko Okada   +5 more
wiley   +1 more source

An ethics framework for consolidating and prioritizing COVID-19 clinical trials

, 2021
Given the dearth of established safe and effective interventions to respond to COVID-19, there is an urgent ethical imperative to conduct meaningful clinical research.
Sugarman, Jeremy, Wilfond, Benjamin S., Magnus, David, Gelinas, Luke, Fernandez Lynch, Holly, Joffe, Steven, Chandros Hull, Sara, Meyer, Michelle N., Bierer, Barbara E., Mohapatra, Seema, Sharp, Richard R., Spector-Bagdady, Kayte, Jeremy Sugarman, Michelle N Meyer, Kayte Spector-Bagdady, David Magnus, Benjamin S Wilfond, Seema Mohapatra, Barbara E Bierer, Sara Chandros Hull, Luke Gelinas, Richard R Sharp, Holly Fernandez Lynch, Steven Joffe   +23 more
core   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Comparison of the completed and discontinued pediatric drug clinical trials in Mainland China: a cross-sectional analysis based on the data from 2003 to 2023

BMC Pediatrics
Background Pediatric drug clinical trials are essential for ensuring the accessibility and safety of medications intended for children. In recent years, the Chinese government has implemented various measures to foster the development of pediatric drug ...
Zi-Ming Wang, Rui-Rui Du, Li Yang
doaj   +1 more source

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

Molecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park, Kyongman An, Gyeonghwa Kim, Soo‐Nyun Choi, Hong‐Ki Lee, Keun Hur, Kyu‐Shik Jeong   +6 more
wiley   +1 more source

Managing clinical trials. [PDF]

, 2010
Managing clinical trials, of whatever size and complexity, requires efficient trial management. Trials fail because tried and tested systems handed down through apprenticeships have not been documented, evaluated or published to guide new trialists ...
Barbara Farrell, Shakur Haleema, Farrell Barbara, Haleema Shakur, Farrell, B, Kenyon, Sara, Shakur, Haleema, Kenyon, Sara; id_orcid, Shakur, H, Kenyon Sara, Sara Kenyon, Farrell, Barbara   +11 more
core   +2 more sources

Preoperative circulating tumor cells integrated with imaging analysis for prognostic evaluation in head and neck squamous cell carcinoma

Molecular Oncology, EarlyView.
Detecting circulating tumor cells (CTCs) in blood before surgery may help predict outcomes in patients with head and neck squamous cell carcinoma (HNSCC). Here, we show when combined with tumor size and lymph node involvement from routine imaging, CTC status identifies high‐risk patients with poorer survival—offering a simple, minimally invasive tool ...
Susanne Flach, Gizem Abaci, Tom Huberty, Axel Lechner, Lukas Käsmann, Jens Ricke, Sophia Stöcklein, Martin Canis, Philipp Baumeister, Marianna Alunni‐Fabbroni   +9 more
wiley   +1 more source

Data Monitoring Committee Usage for Trials Registered on ClinicalTrials.gov

, 2022
Independent Data Monitoring Committees (DMC) play an important role in clinical trial oversight. In 2010 Califf et al. analyzed DMC use for trials registered on ClinicalTrials.gov from 2000-2010, based on voluntary responses to the “Data Monitoring ...
Nora Hutchinson
core   +1 more source

ESTADO DEL ARTE EN LAS REVISTAS MÉDICAS EN EL SIGLO XXI

Revista Médica Clínica Las Condes, 2019
Resumen: Las revistas médicas publican manuscritos médicos científicos, verifican su autenticidad, diseminan su contenido y lo archivan. Ello las convierte en reflejos del estado actual de la medicina, repositorios de experiencias clínicas, vías de ...
Humberto Reyes
doaj   +1 more source

Epigenetic silencing of the liver‐specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation

Molecular Oncology, EarlyView.
LUNAR is a liver‐specific long noncoding RNA (lncRNA) that is highly expressed in normal liver but becomes epigenetically silenced in hepatocellular carcinoma through promoter hypermethylation. Loss of LUNAR is associated with NOTCH activation, epithelial–mesenchymal transition, and metastasis, whereas restoring LUNAR restrains metastatic progression ...
Se Ha Jang, Hyung Seok Kim, Geum Ok Baek, Moon Gyeong Yoon, Su In Lee, Jee‐Yeong Jeong, Ji Eun Han, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun   +9 more
wiley   +1 more source